113 related articles for article (PubMed ID: 24682418)
1. Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway.
Lévesque E; Laverdière I; Audet-Walsh E; Caron P; Rouleau M; Fradet Y; Lacombe L; Guillemette C
Clin Cancer Res; 2014 Jun; 20(11):2971-83. PubMed ID: 24682418
[TBL] [Abstract][Full Text] [Related]
2. The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy.
Audet-Walsh É; Bellemare J; Lacombe L; Fradet Y; Fradet V; Douville P; Guillemette C; Lévesque É
Eur Urol; 2012 Jul; 62(1):88-96. PubMed ID: 22209174
[TBL] [Abstract][Full Text] [Related]
3. Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression.
Lévesque É; Huang SP; Audet-Walsh É; Lacombe L; Bao BY; Fradet Y; Laverdière I; Rouleau M; Huang CY; Yu CC; Caron P; Guillemette C
Clin Cancer Res; 2013 Feb; 19(3):699-709. PubMed ID: 23186779
[TBL] [Abstract][Full Text] [Related]
4. The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness.
Sun T; Oh WK; Jacobus S; Regan M; Pomerantz M; Freedman ML; Lee GS; Kantoff PW
Cancer Prev Res (Phila); 2011 Dec; 4(12):2044-50. PubMed ID: 21900597
[TBL] [Abstract][Full Text] [Related]
5. Genetic variants of the CYP1B1 gene as predictors of biochemical recurrence after radical prostatectomy in localized prostate cancer patients.
Gu CY; Qin XJ; Qu YY; Zhu Y; Wan FN; Zhang GM; Sun LJ; Zhu Y; Ye DW
Medicine (Baltimore); 2016 Jul; 95(27):e4066. PubMed ID: 27399092
[TBL] [Abstract][Full Text] [Related]
6. Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway.
Cornu JN; Audet-Walsh E; Drouin S; Bigot P; Valeri A; Fournier G; Azzouzi AR; Roupret M; Cormier L; Chanock S; Guillemette C; Cussenot O; Lévesque E; Cancel-Tassin G
World J Urol; 2017 Feb; 35(2):293-298. PubMed ID: 27277477
[TBL] [Abstract][Full Text] [Related]
7. Genetic predisposition to early recurrence in clinically localized prostate cancer.
Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
[TBL] [Abstract][Full Text] [Related]
8. Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.
Price DK; Chau CH; Till C; Goodman PJ; Leach RJ; Johnson-Pais TL; Hsing AW; Hoque A; Parnes HL; Schenk JM; Tangen CM; Thompson IM; Reichardt JK; Figg WD
Cancer; 2016 Aug; 122(15):2332-40. PubMed ID: 27164191
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy.
Huang CN; Huang SP; Pao JB; Hour TC; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Wu PP; Huang CY; Hsieh CJ; Bao BY
J Intern Med; 2012 May; 271(5):499-509. PubMed ID: 21880074
[TBL] [Abstract][Full Text] [Related]
10. Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness.
Cicek MS; Liu X; Casey G; Witte JS
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2173-7. PubMed ID: 16172228
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer risk variants are not associated with disease progression.
Szulkin R; Holmberg E; Stattin P; Xu J; Zheng S; Palmgren J; Grönberg H; Wiklund F
Prostate; 2012 Jan; 72(1):30-9. PubMed ID: 21520160
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase-2 polymorphism is associated with prognosis in prostate cancer.
dos Reis ST; Villanova FE; Andrade PM; Pontes J; de Sousa-Canavez JM; Sañudo A; Antunes AA; Dall'oglio MF; Srougi M; Moreira Leite KR
Urol Oncol; 2010; 28(6):624-7. PubMed ID: 19117773
[TBL] [Abstract][Full Text] [Related]
13. Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk.
Sainz J; Rudolph A; Hein R; Hoffmeister M; Buch S; von Schönfels W; Hampe J; Schafmayer C; Völzke H; Frank B; Brenner H; Försti A; Hemminki K; Chang-Claude J
Endocr Relat Cancer; 2011 Apr; 18(2):265-76. PubMed ID: 21317201
[TBL] [Abstract][Full Text] [Related]
14. Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population.
Oh JJ; Byun SS; Lee SE; Hong SK; Jeong CW; Kim D; Kim HJ; Myung SC
Gene; 2014 Jan; 533(1):86-93. PubMed ID: 24120391
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.
Cunningham JM; Hebbring SJ; McDonnell SK; Cicek MS; Christensen GB; Wang L; Jacobsen SJ; Cerhan JR; Blute ML; Schaid DJ; Thibodeau SN
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):969-78. PubMed ID: 17507624
[TBL] [Abstract][Full Text] [Related]
16. The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer.
Justenhoven C; Pierl CB; Haas S; Fischer HP; Baisch C; Hamann U; Harth V; Pesch B; Brüning T; Vollmert C; Illig T; Dippon J; Ko YD; Brauch H
Breast Cancer Res Treat; 2008 Sep; 111(1):171-7. PubMed ID: 17922187
[TBL] [Abstract][Full Text] [Related]
17. Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer.
Cussenot O; Azzouzi AR; Bantsimba-Malanda G; Gaffory C; Mangin P; Cormier L; Fournier G; Valeri A; Jouffe L; Roupret M; Fromont G; Sibony M; Comperat E; Cancel-Tassin G
Clin Cancer Res; 2008 Sep; 14(17):5635-9. PubMed ID: 18765558
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP1A1, GSTM1, and GSTT1 polymorphisms in overall and specific prostate cancer survival.
Acevedo CA; Quiñones LA; Catalán J; Cáceres DD; Fullá JA; Roco AM
Urol Oncol; 2014 Apr; 32(3):280-90. PubMed ID: 24508281
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer.
Dos Reis ST; Pontes J; Villanova FE; Borra PM; Antunes AA; Dall'oglio MF; Srougi M; Leite KR
J Urol; 2009 May; 181(5):2320-5. PubMed ID: 19303106
[TBL] [Abstract][Full Text] [Related]
20. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
